Home › Diffuse Large B-Cell Lymphoma › Connecticut
Diffuse Large B-Cell Lymphoma clinical trials in Connecticut
8 studies for Diffuse Large B-Cell Lymphoma are looking for participants at sites in Connecticut.
Cities in Connecticut
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
- Smilow Cancer Hospital-Derby Care Center, Derby
- Smilow Cancer Hospital Care Center - Guilford, Guilford
- Yale University, New Haven
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT06649812A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
- Yale University School of Medicine - Yale Cancer Center, New Haven
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07101328Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Yale New Haven Hospital ( Site 1012), New Haven
RecruitingPhase 1/2
6 Months – 25 Years · All sexes · Updated Sep 17, 2026 · NCT06395103Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma
- Yale University, New Haven
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 10, 2026 · NCT05272384Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU
- Yale University, New Haven
RecruitingObservational study
Ages 18 and older · All sexes · Updated Aug 5, 2026 · NCT06116110DALY II USA/ MB-CART2019.1 for DLBCL
- Yale University, New Haven
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 13, 2026 · NCT04792489A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- Yale Cancer Center, New Haven
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 2, 2026 · NCT05131022Hyperfractionated Dual Equivalent Fractionated Radiation Therapy
- Yale University, New Haven
Recruiting
Ages 18 and older · All sexes · Updated Jun 22, 2026 · NCT06898905From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.